Biologic Agents for the Treatment of Chronic Rhinosinusitis With Nasal Polyps

2018 ◽  
Vol 33 (2) ◽  
pp. 203-211 ◽  
Author(s):  
Alison G. Kartush ◽  
Jane K. Schumacher ◽  
Rachna Shah ◽  
Monica O. Patadia
Keyword(s):  
Clinical Trials ◽  
Chronic Rhinosinusitis ◽  
Nasal Polyposis ◽  
Biologic Therapy ◽  
Biologic Agents ◽  
Inflammatory Disorder ◽  
Review Of Literature ◽  
Sinus Disease ◽  
Adjunct Treatment

Background Chronic rhinosinusitis with nasal polyposis is a complex inflammatory disorder, which is often recalcitrant to medical and surgical management. Recently, biologic agents have been studied as an adjunct treatment for this patient population. Objective The purpose of this study is to examine the role of biologic agents for chronic rhinosinusitis patients by reviewing literature and clinical trials. Methods A comprehensive review of literature and clinical trials—both recently completed and ongoing—was undertaken to examine up-to-date evidence of current biologic therapy and its role in chronic rhinosinusitis patients—including anti-IgE, anti-IL-4, anti-IL-5, anti-IL-13, and GATA-3 DNAzyme. Results Specific biologic agents discussed include omalizumab, reslizumab, mepolizumab, benralizumab, dupilumab, and Hgd40/SB010. Risks, side effects, and administration information are also reviewed. An algorithm for the use of biologics in patients with chronic rhinosinusitis with nasal polyposis is proposed. Conclusion These treatments have promising results and may prove to be an important adjunct for patients with recalcitrant sinus disease.

The role of biologic therapy in phase II breast cancer clinical trials.

2011 ◽  
Vol 29 (15_suppl) ◽  
pp. e13048-e13048
Author(s):  
K. Patel ◽  
A. Kamal ◽  
T. Zhang ◽  
A. Schneider ◽  
E. P. Hamilton ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Clinical Trials ◽  
Phase Ii ◽  
Biologic Therapy ◽  
Cancer Clinical Trials

scholarly journals The Role of Biologics in Chronic Rhinosinusitis With Nasal Polyps

2020 ◽  
Vol 100 (1) ◽  
pp. 44-47
Author(s):  
Gayatri B. Patel ◽  
Anju T. Peters
Keyword(s):  
Cost Effectiveness ◽  
Chronic Rhinosinusitis ◽  
Nasal Polyps ◽  
Biologic Therapy ◽  
Phase 3 ◽  
Multiple Factors ◽  
Treatment Paradigm ◽  
New Treatment

Biologic therapy is a new treatment option for patients with chronic rhinosinusitis with nasal polyps (CRSwNP). Currently, the only biologic with Food and Drug Administration–approval status for CRSwNP is dupilumab. Several other biologics are likely to be approved for CRSwNP, including mepolizumab and omalizumab, based on their promising phase 3 trial results. The role of biologics in the treatment paradigm requires consideration of multiple factors that have yet to be clearly established. This includes identifying patients most appropriate for biologic therapy while considering long-term safety and cost-effectiveness in the context of patient preferences and goals.

Dupilumab in the treatment of chronic rhinosinusitis with nasal polyposis

Immunotherapy ◽  
2020 ◽  
Vol 12 (2) ◽  
pp. 111-121 ◽  
Author(s):  
John V Boyle ◽  
Kent Lam ◽  
Joseph K Han
Keyword(s):  
Chronic Rhinosinusitis ◽  
Patient Reported Outcomes ◽  
Nasal Polyposis ◽  
Biologic Therapy ◽  
Patient Reported ◽  
The Us ◽  
Us Fda ◽  
Underlying Mechanisms ◽  
Novel Agent

Chronic rhinosinusitis with nasal polyposis (CRSwNP) imparts a significant healthcare challenge, resulting in diminished quality of life for patients and high costs with resource utilization for disease management. Understanding of CRSwNP pathophysiology has progressively evolved and the identification of various inflammatory biomarkers has led to the development of monoclonal antibodies that target the underlying mechanisms of inflammation. Dupilumab, which targets IL-4 and IL-13 signaling, serves as a novel agent for CRSwNP treatment. Three clinical trials, NCT01920893, SINUS-24 and SINUS-52, have shown that dupilumab improves both subjective patient-reported outcomes and objective physician-evaluated metrics for CRSwNP. The favorable findings have resulted in approval by the US FDA in June 2019 as the first biologic therapy for CRSwNP.

Pharmacotherapy of Juvenile Idiopathic Arthritis

2008 ◽  
Vol 22 (1) ◽  
pp. 17-28 ◽  
Author(s):  
Edward A. Bell
Keyword(s):  
Clinical Trials ◽  
Juvenile Idiopathic Arthritis ◽  
Initial Therapy ◽  
Biologic Agents ◽  
Rheumatic Disorder ◽  
Inflammatory Drugs ◽  
Anti Inflammatory ◽  
Therapy Methotrexate

Juvenile idiopathic arthritis is the most common rheumatic disorder of childhood, and is defined as arthritis beginning prior to the age of 16 years, lasting more than 6 weeks, with an unknown cause. Seven subtypes of juvenile idiopathic arthritis have recently been categorized and named. These subtypes differ broadly in the number of affected joints and the presence of systemic illness. Although many children with juvenile idiopathic arthritis may achieve remission prior to entering adulthood, many others will continue to have debilitating disease into adulthood. Pharmacotherapy plays a major role in the treatment of juvenile idiopathic arthritis. Nonsteroidal anti-inflammatory drugs and corticosteroids can be beneficial for many children and are used as initial therapy. Methotrexate may offer benefits to children unresponsive to these initial agents. Studies evaluating the use of several biologic agents and immunosuppressants have recently been published, and the role of these drugs for children with juvenile idiopathic arthritis is being assessed. Major clinical trials and pediatric implications are reviewed.

scholarly journals Chronic rhinosinusitis with nasal polyposis: the role of personalized and integrated medicine

2021 ◽  
Author(s):  
Giorgio Ciprandi ◽  
Matteo Gelardi
Keyword(s):  
Personalized Medicine ◽  
Chronic Rhinosinusitis ◽  
Nasal Polyposis ◽  
Biological Agents ◽  
Point Of View ◽  
Integrated Medicine ◽  
Intranasal Corticosteroids ◽  
Ideal Candidate ◽  
The Ideal

Chronic rhinosinusitis with nasal polyposis (CRSwNP) is a common disorder. From a clinical and immunopathological point of view, different phenotypes and endotypes have been identified. As asthma is frequent comorbidity, biological agents for treating CRSwNP associated with asthma may be an attractive strategy. Biological agents have several mechanisms, such as antagonizing IgE, interleukin (IL) 4, IL-5, and IL-13. However, a workup is mandatory, mainly concerning pheno-endotyping. In this regard, clinical cytological grading (CCG) has been proposed as a useful tool to manage patients with CRSwNP as it allows us to define clinical and immunopathological phenotypes able to identify the ideal candidate for biologics. In particular, the mixed cellular pattern, such as eosinophils and mast cells, could be sensitive to anti-IL-4 agents. There is still a need for well-established indications, criteria of responsiveness, duration, and safety. Moreover, personalized medicine could be opportunely integrated and/or alternated with intranasal corticosteroids to prevent relevant adverse events.

scholarly journals Anti-inflammatory Treatment and Cardiovascular Outcomes: Results of Clinical Trials

2021 ◽  
Vol 16 ◽  
Author(s):  
Alberto J Lorenzatti
Keyword(s):  
Clinical Trials ◽  
Arterial Wall ◽  
Plaque Formation ◽  
Phase Iii ◽  
Inflammatory Disorder ◽  
Chronic Inflammatory Disorder ◽  
Phase Iii Clinical Trials ◽  
Cytokines And Chemokines ◽  
Pro Inflammatory Cytokines

Atherosclerosis is a chronic inflammatory disorder of the vasculature where cholesterol accumulates in the arterial wall stimulating infiltration of immune cells. This plays an important role in plaque formation, as well as complications caused by its build up. Pro-inflammatory cytokines and chemokines are implicated throughout the progression of the disease and different therapies that aim to resolve this chronic inflammation, reduce cardiovascular (CV) events and improve clinical outcomes have been tested. The results from the pivotal CANTOS trial show that targeting the pro-inflammatory cytokine IL-1β successfully reduces the incidence of secondary CV events. This review briefly assesses the role of inflammation in atherosclerosis, providing a picture of the multiple players involved in the process and offering a perspective on targeting inflammation to prevent atherosclerotic CV events, as well as focusing on the results of the latest Phase III clinical trials.

Sign in / Sign up

Export Citation Format

Share Document